close read more

The future Servier Paris-Saclay Research Institute within a cluster of academic excellence


The future Servier Paris-Saclay Research Institute within a cluster of academic excellence

For its 18th edition, the Academic Ranking of World Universities, better known as the Shanghai ranking list, places a French university in the top 15 for the first time. It is the University of Paris-Saclay, which takes 14th place for its first appearance in the ranking!

This is excellent news for Servier which, with the Servier Paris-Saclay Research Institute, will consolidate the research activities of its four French sites within this unique innovation cluster by 2022*.

The Servier Paris-Saclay Research Institute represents a major step for the Servier Group in achieving more open, dynamic, and productive research that serves patients. In time, 600 Servier researchers will be working together in a single location dedicated to interdisciplinary innovation in the Paris-Saclay cluster.

Founded at the end of 2019, the Paris-Saclay experimental establishment combines four major schools (AgroParisTech, CentraleSupélec, Ecole normale supérieure Paris-Saclay, Institut d’optique graduate school) and seven research laboratories (CEA, CNRS, IHES, Inria, Inserm, Onéra) with the former University of Paris-Sud. Counting 48,000 students and 9,000 professors and teachers/researchers, the University of Paris-Saclay is a driving force for the development of its region and is open to the world with an international label of excellence.



This ranking confirms the Servier Group’s choice to combine its research activities and its desire to strengthen its partnerships within the Paris-Saclay cluster.

Discover the complete Shanghai ranking (http://www.shanghairanking.com/ARWU2020.html)

Discover the video of the future institute

*expected date before the Covid-19 context

Last news

Meeting the challenge of adherence: a Servier study presented at the ESH 2022 Annual Meeting!
Appointment of Angelo Paci, Oncology & Immuno-Oncology Program Leader
Patient associations’ perception of pharmaceutical companies: Servier is making progress!